Aura Biosciences to Participate in Upcoming Investor Conference
Aura Biosciences (NASDAQ: AURA) will participate in the Stifel 2026 Healthcare Conference on November 10, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Aura Biosciences (NASDAQ: AURA) will participate in the Stifel 2026 Healthcare Conference on November 10, 2026. CEO and President Natalie Holles will join a fireside chat at 2:40 p.m. ET. A live webcast will be available through the company’s Investors & Media page under Events & Presentations, with a replay archived for 90 days following the presentation.
Details
News Market Reaction – AURA
On Nov 4, the first trading day after this news, AURA closed 6.57% above the previous close. Argus tracked a peak move of +2.5% during that session. Our momentum scanner recorded 18 alerts for this stock that day.
Data tracked by StockTitan Argus for the Nov 4 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers, today announced that Natalie Holles, CEO and President, will participate in the following upcoming investor conference:
- Stifel 2026 Healthcare Conference on Tuesday, November 10, 2026.
- Fireside chat at 2:40 p.m. ET
The live webcast of the fireside chat will be available on the “Investors & Media” page under the “Events & Presentations” section of the Company’s website at https://ir.aurabiosciences.com/events-and-presentations, where a replay of the webcast will be archived for 90 days following the presentation date.
About Aura Biosciences
Aura Biosciences is a clinical-stage biotechnology company developing bel-sar, a potentially transformative, first-in-class front-line vision-preserving therapy for patients living with ocular cancers. Bel-sar represents an entirely novel approach to treating ocular cancers via its dual mechanisms of action of acute tumor necrosis and secondary anti-tumor immune activation. The Phase 3 registration study of Bel-sar in early choroidal melanoma, the largest patient segment of uveal melanoma, is fully enrolled, and earlier stage studies in metastases to the choroid and cancers of the ocular surface are ongoing. Aura's mission is to improve outcomes for patients living with ocular cancers by delivering a therapy that not only arrests tumor growth but also preserves vision and quality of life.
For more information, visit aurabiosciences.com. Follow us on X, @AuraBiosciences, and visit us on LinkedIn.
Investor and Media Relations Contact:
Alex Dasalla
Head of Corporate Affairs
